文献速递前列腺癌

生化与遗传联合的前列腺癌风险分层

Joint Biochemical and Genetic Prostate Cancer Risk Stratification.
PubMed 文献 · J Urol · 2025-11-21

研究在310名基线PSA≥1 ng/mL的匹配前瞻性队列中计算前列腺癌多基因风险评分PHS290,用回归模型预测临床风险组。PHS290可将人群分层并识别中高危前列腺癌,将其加入模型后对中高危前列腺癌时间的预测优于现有活检前5年风险计算器。

要点

  • 基线PSA≥1 ng/mL男性中,PHS290可分层并识别中高危前列腺癌。
  • PHS290联合临床协变量和5年风险计算器可改善预测。
  • 遗传评分有望用于分级筛查策略,但需大队列进一步验证。

核心结论

  • 在基线PSA≥1 ng/mL男性中,PHS290可进行前列腺癌风险分层并识别中高危患者。
  • 将PHS290加入预测模型可改善对中高危前列腺癌时间的预测,优于现有活检前5年风险计算器。
  • 遗传评分在分级筛查策略中具有潜力,但需在大规模队列中进一步研究。

研究设计与样本

  • 研究为多样本、匹配的前瞻性队列,纳入310名基线PSA≥1 ng/mL且伴或不伴前列腺癌的男性。
  • 计算前列腺癌诊断风险的多基因风险评分PHS290,并使用回归模型结合临床协变量和现有5年风险计算器评分预测前列腺癌临床风险组。

主要发现

  • PHS290将PSA≥1 ng/mL个体分层为不同风险组,并识别出中危和高危前列腺癌患者。
  • 在预测中危和高危前列腺癌时间的模型中,加入PHS290后预测效果优于现有活检前5年风险计算器。

临床怎么用

  • 对基线PSA≥1 ng/mL的男性,可考虑将PHS290纳入风险评估以辅助识别中高危前列腺癌。
  • 遗传评分可能优化分级筛查策略,但当前证据尚不足以直接改变临床实践。

局限性

  • 研究样本量为310人,结论需在更大规模队列中验证。
  • PHS290在分级筛查策略中的风险分层能力尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Overdiagnosis of prostate cancer (PC) through PSA testing at short intervals remains common. While baseline serum PSA abundance < 1 ng/mL warrants infrequent screening, it is critical to foster advanced diagnostic practices for men with baseline serum PSA ≥ 1 ng/mL, who are at higher risk for clinically significant disease. We investigated whether common germline variants could enhance screening recommendations in men with PSA ≥ 1 ng/mL. MATERIALS AND METHODS: Polygenic hazard scores (PHS) for the risk of PC diagnosis (PHS290) were computed in a diverse, matched, prospective cohort of 310 men with baseline PSA ≥ 1 ng/mL with or without PC. Regression models were used to predict PC clinical risk groups with PHS290, while incorporating clinical covariates and an existing 5-year risk calculator score. RESULTS: PHS290 stratified individuals with PSA ≥ 1 ng/mL into risk groups and identified men with intermediate-risk and high-risk PC. Adding PHS290 to our model for predicting time to intermediate-risk and high-risk PC improved predictions over an existing prebiopsy 5-year risk calculator. CONCLUSIONS: Our study demonstrates the potential of genetic scores to advance screening guidance. The PC risk stratification capabilities of molecular biomarkers in tiered screening strategies merit further study in large cohorts.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zeltser N, Haas R, Ibilibor C, et al. Joint Biochemical and Genetic Prostate Cancer Risk Stratification. J Urol. 2025. PMID: 41270226. doi:10.1097/JU.0000000000004859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。